HIV progress has been real, but the epidemic still bends toward violence and money
Global HIV trends improved between 2003 and 2023, yet the trajectory is neither smooth nor secure. New infections fell from 2.85 million to 2.06 million, and HIV-related deaths dropped from a peak of 1.71 million in 2004 to 0.83 million in 2023. At the same time, the number of people living with HIV/AIDS climbed from 26.3 million to 42.4 million, a pattern that reflects longer survival as antiretroviral therapy expanded across many settings.
The burden is no longer defined only by viral control. It is also shaped by gendered exposure to violence, uneven regional progress, and the possibility that future financing losses could reverse hard-won gains.
Survival gains widened the pool of people living with HIV
The increase in people living with HIV is not a sign of worsening transmission by itself. It also marks the success of treatment programs that keep people alive longer, shifting HIV from a rapidly fatal infection toward a chronic condition in many settings. When ART coverage rises, mortality falls faster than prevalence, and prevalence can climb even as the epidemic becomes less lethal.
By 2023, females still carried a higher HIV prevalence than males, with 23.4 million women and girls living with HIV compared with 19.1 million males. The incidence gap between females and males has narrowed substantially, but the persistence of higher prevalence in women signals the cumulative effect of biological susceptibility, social vulnerability, and delayed access in some regions. A shrinking incidence gap does not erase the long tail of earlier infections.
Sub-Saharan Africa improved, while eastern Europe and central Asia moved in the opposite direction
Regional trends were far from uniform. Sub-Saharan Africa recorded the steepest gains, with incidence falling 64.3% and mortality falling 74.6% between 2003 and 2023. Those declines are consistent with large-scale ART rollout, prevention programs, and improved testing and linkage to care.
Elsewhere, the picture was harsher. Central Europe, eastern Europe, and central Asia saw incidence rates rise by 232.1% and mortality rates increase by 37.8% over the same period. Such divergence points to different epidemic drivers, uneven prevention coverage, and health systems that have not translated treatment advances into population-level control. The global average can hide these opposing regional currents, and HIV policy fails when it treats them as one epidemic with one solution.
Intimate partner violence accounted for a measurable share of deaths among women
The analysis puts a numerical frame around a clinical and social reality long understood but often undercounted: intimate partner violence contributes to HIV risk and to worse outcomes once infection occurs. Among females aged 15 years and older globally in 2023, IPV was associated with an estimated 10.7% of HIV-related deaths, or about 40,700 deaths. The population attributable fraction was highest in Oceania, central sub-Saharan Africa, and eastern sub-Saharan Africa.
The pathway is biologically and socially plausible. Violence can increase exposure through coerced sex and reduce the ability to negotiate condom use or seek testing. It can also disrupt treatment adherence, deter clinic attendance, and drive mental health stressors that erode continuity of care. In practical terms, HIV prevention and HIV survival are both weakened when safety at home is absent.
IPV is not a peripheral social variable in this dataset. It is part of the mortality structure.
Funding cuts could erase treatment coverage and drive new infections
The most alarming finding sits in the forecast. Using a non-parametric stochastic frontier approach to model how development assistance influences ART coverage, the analysis projected that funding reductions could lower global ART coverage by 8.1% between 2025 and 2030. That contraction would not stay abstract; it would translate into roughly 1.6 million new HIV infections among females and 1.3 million among males, along with 790,600 HIV-related deaths among females and 670,600 among males.
These projected harms fall most heavily in sub-Saharan Africa. The mechanism is straightforward: less financing leads to weaker treatment access, lower viral suppression, and more onward transmission. When ART coverage slips, the epidemic does not pause. It accelerates through both preventable infections and excess mortality.
The forecast also reveals a structural truth about HIV control. Progress is cumulative, but so is fragility. If program funding weakens, the benefits of years of scale-up can unravel quickly, especially in regions where health systems remain dependent on external support.
A gender-responsive HIV response has to include violence prevention
The findings support a broader clinical and public health response than ART alone. HIV programs that ignore violence prevention are missing part of the causal chain, especially for women and girls. Screening for IPV, offering post-violence care, strengthening referral pathways, and integrating psychosocial support with HIV services are not optional add-ons; they are part of reducing mortality.
At the same time, maintaining financing is a treatment issue, not just a budget issue. ART keeps people alive, suppresses viral load, and reduces transmission. Financing cuts threaten all three. The forecasted decline in coverage places a concrete number on a risk that health systems already know well: when access contracts, mortality returns.
The 2030 target now depends on two separate defenses
The UNAIDS 2030 goals remain technically achievable only if two pressures are addressed together. HIV control must be protected from financial erosion, and women’s HIV risk must be addressed in settings where violence shapes exposure, care-seeking, and survival. Those forces operate on different levels, but the epidemic records them in the same ledger.
GBD 2023 makes the cost of inaction visible. The remaining burden is no longer concentrated only in untreated infection; it is also tied to social harm and policy instability. Without durable financing and integrated protection from intimate partner violence, the next five years could bring a measurable reversal in both incidence and mortality.